Bioequivalence of Dutasteride 0.5 mg vs Avodart in Healthy Thai Males

Phase 1, randomised, open-label trial of dutasteride in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Bio-innova. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration at 72 hours and Maximal measured plasma concentration at 72 hours. Planned start Sep 2024; status: not yet recruiting.